PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsInterferon alfa-2a
Interferon alfa-2a
Roferon-A (interferon alfa-2a) is a protein pharmaceutical. Interferon alfa-2a was first approved as Roferon-a on 1986-06-04. It is used to treat brain neoplasms, chronic hepatitis c, colorectal neoplasms, cryoglobulinemia, and essential thrombocythemia amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
digestive system diseasesD004066
nervous system diseasesD009422
eye diseasesD005128
urogenital diseasesD000091642
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
immune system diseasesD007154
Show 1 more
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Interferon alfa-2a
Tradename
Proper name
Company
Number
Date
Products
Roferon-Ainterferon alfa-2aRocheN-103145 DISCN1986-06-04
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L03: Immunostimulants
— L03A: Immunostimulants
— L03AB: Interferons
— L03AB04: Interferon alfa-2a
HCPCS
Code
Description
S0145
Injection, pegylated interferon alfa-2a, 180 mcg per ml
Clinical
Clinical Trials
423 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HepatitisD006505—K75.911223231674
Hepatitis aD006506EFO_0007305B1511223231674
Hepatitis cD006526—B19.21613151348
Chronic hepatitis cD019698EFO_0004220B18.21911121548
Hepatitis bD006509———61010226
Chronic hepatitis bD019694EFO_0004239B18.1—5911226
Chronic hepatitisD006521—K73.9—276216
Hiv infectionsD015658EFO_0000764B202441—10
Acquired immunodeficiency syndromeD000163EFO_0000765B2011—114
AnemiaD000740EFO_0004272D64.9———1—1
Show 6 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal cell carcinomaD002292EFO_0000376——42—27
InfectionsD007239EFO_0000544—122——5
Chronic hepatitis dD019701———12—14
Hepatitis dD003699EFO_0007304——12—14
Essential thrombocythemiaD013920—D47.3111——3
Polycythemia veraD011087—D45111——3
ThrombocytosisD013922—D75.83111——3
PolycythemiaD011086EFO_0005804D75.1111——3
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340——13——3
LeukemiaD007938—C95——2——2
Show 6 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Communicable diseasesD003141——11———2
Aids-related complexD000386EFO_0007137B2011———2
CarcinomaD002277—C80.0—1———1
NeoplasmsD009369—C80—1———1
AdenocarcinomaD000230———1———1
Margins of excisionD000072662———1———1
Hepatocellular carcinomaD006528—C22.0—1———1
Liver neoplasmsD008113EFO_1001513C22.0—1———1
Treatment failureD017211———1———1
DepressionD003863—F33.9—1———1
Show 2 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———1————1
Papillomavirus infectionsD030361——1————1
Anus neoplasmsD001005EFO_0003835C211————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HivD006678—O98.7————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameInterferon alfa-2a
INN—
Description
Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B. For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%. For hepatitis B it may be used alone. It is given by injection under the skin.
Classification
Protein
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI120608
ChEMBL IDCHEMBL2108508
ChEBI ID—
PubChem CID—
DrugBankDB00008
UNII ID—
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 45 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
30,662 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use